SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced fourth quarter and full year fiscal 2026 financial results for the period ended January 31, 2026.Revenue for the fourth quarter of fiscal 2026 was $100.9 million, up 20.1% from $84.0 million in the same period in fiscal 2025. For the fiscal year ended January 31, 2026, revenue was $390.7 million, up 37.2% from $284.9 million for the fiscal year ended January 31, 2025. Gross margin under U.S. generally accepted accounting principles (GAAP) for the fourth quarter of fiscal 2026 was 58.4%, compared with 60.0% for the same period in fiscal 2025. For the fiscal year ended January 31, 2026, GAAP gross margin was 59.2%, compared with 60.5% for the fiscal year ended January 31, 2025. GAAP net loss for...

Fourth quarter and full year 2025 revenue exceeded guidance FRAMINGHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced financial results for the quarter and full year ended December 31, 2025.  Fourth Quarter 2025 Financial Highlights:Revenue was $61.5 million, a decrease of 1% from $62.3 million in Q4 2024. Net Loss, inclusive of goodwill impairment charges of $19.5 million, was $(17.1) million, or (28)% of revenue, compared to $(84.7) million in Q4 2024, inclusive of goodwill impairment charges of $97.1 million, or (136)% of revenue. Adjusted Net Income was $8.6 million, compared to $12.6 million in Q4 2024. Adjusted EBITDA was $18.0 million, or 29% of revenue, compared to...

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior year Full Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior year Full Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior year Full Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior year Full Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of 54%, an expansion of 1,900 bps and 900 bps, respectively, versus prior year Full Year 2025 Adjusted EBITDA of $205.0 million, compares favorably...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsGenerated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025 Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025 Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insight Strong presence at the 2025 Human Proteome Organization World Congress with more than a dozen scientific presentations and sixteen posters...

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December       Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing’s Syndrome to Initiate in the First Half of 2026       Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates               Management Hosting Conference Call at 4:30 p.m. ET Today         SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a breakout year for...

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 HighlightsTotal revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of total revenueAdjusted EBITDA in the year ended December 31, 2025 was $5.0 million, compared to $22.4 million for the full year 2024Expanded...

Initiates Non-GAAP 30% Rule of 40 Target By the Fourth Quarter of 2027 Approximated Subscription Revenue Contribution for ≥$30K ARR Customers Grew 22% in 2025 CHICAGO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2025. “Our team delivered strong results in the fourth quarter, highlighted by 15% total RPO growth and strong non-GAAP profitability,” said Ryan Barretto, CEO of Sprout Social. “We are announcing a new operating goal of reaching 30% on a non-GAAP basis against a Rule of 40 framework by fourth quarter 2027 as well as making continued investments to expand our reach deeper into the $30K+ customer segment, which...

Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following:Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront payment and is entitled to potential milestone payments exceeding $200 million for each...

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025. “We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to deliver meaningful impact for patients and clinicians every day,” said Derek Maetzold, president and chief executive officer of Castle Biosciences....

2025 marked the second full year of operation for all four vessels operated by Havila Kystruten AS (HKY) along the Norwegian coast. The year represents a clear step forward for the Company, reflecting improved operational stability, stronger commercial performance, and the effect of targeted investments made to support long term growth. In its second year of full operation, the fleet achieved exceptional operational uptime of 100% for the full year, up from 98% in 2024. These results are particularly strong given the operation of four new vessels and are a testament to the professionalism and dedication of the crew on board. The performance also reflects the benefits of a modern operating model, including an availability-based power by the hour arrangement with Kongsberg Maritime, which enables 24/7 monitoring and proactive technical management...